Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer

Tung-Yi Lin1,2, Hsien-Yeh Hsu1,2,3, Wei-Hsuan Sun2

  • 1Program in Molecular Medicine, National Yang-Ming University and Academia Sinica, Taipei, Taiwan.

Insights

Recombinant LZ-8 (rLZ-8), a mushroom protein, halts lung cancer growth by promoting the degradation of epidermal growth factor receptor (EGFR). This novel mechanism inhibits EGFR signaling, offering a potential new cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Activating mutations in the epidermal growth factor receptor (EGFR) are linked to lung cancer.
  • EGFR signaling pathways are crucial for cancer cell proliferation and survival.

Purpose of the Study:

  • To investigate the anti-cancer effects of recombinant LZ-8 (rLZ-8) from Ganoderma lucidum on lung cancer cells.
  • To elucidate the mechanism by which rLZ-8 affects EGFR expression and downstream signaling.

Main Methods:

  • Cell culture and treatment with rLZ-8.
  • Western blotting to assess protein expression (EGFR, AKT, ERK1/2).
  • Mouse xenograft models to evaluate tumor growth inhibition.
  • Analysis of EGFR localization, degradation, and complex formation with Cbl.

Main Results:

  • rLZ-8 induced cell cycle arrest and apoptosis in lung cancer cells.
  • rLZ-8 downregulated wild-type and mutated EGFR expression and inhibited AKT/ERK1/2.
  • rLZ-8 suppressed tumor growth and EGFR expression in vivo.
  • rLZ-8 promoted EGFR degradation by enhancing its ubiquitination and Cbl complex formation.

Conclusions:

  • rLZ-8 exhibits anti-cancer properties by promoting EGFR degradation, offering a novel therapeutic strategy.
  • Targeting EGFR degradation represents a promising approach for treating lung cancer, particularly those with EGFR mutations or overexpression.